Summary & Overview
CPT 0570U: i–STAT TBI Blood/Plasma Test for GFAP and UCH‑L1
CPT code 0570U is a Proprietary Laboratory Analyses (PLA) code that identifies the i–STAT TBI test from Abbott Point of Care, a blood/plasma assay measuring GFAP and UCH‑L1 biomarkers. The test yields individual biomarker values and an overall binary result (elevated or nonelevated) used to detect brain injury. Nationally, this code matters because it standardizes reporting for a single-manufacturer point-of-care diagnostic that can influence emergency department triage and imaging decisions.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical purpose and service setting, payer coverage considerations, and common billing modifiers tied to laboratory and point-of-care testing. The publication covers benchmark reporting where available, relevant policy developments affecting PLA codes, and clinical context about GFAP and UCH‑L1 use in acute brain injury evaluation.
This summary is intended to inform coding, billing, and policy stakeholders about the clinical role and billing identity of the i–STAT TBI assay under CPT code 0570U, and what to expect in payer coverage and administrative handling of this single-source diagnostic service.
Billing Code Overview
CPT code 0570U is a Proprietary Laboratory Analyses (PLA) code that applies only to a single, specific laboratory test: the i–STAT TBI from Abbott Point of Care. The test measures two brain-injury–associated proteins, glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl–terminal hydrolase L1 (UCH‑L1), in blood or plasma. Results for each biomarker are reported individually and are combined into an overall result of either elevated or nonelevated based on a predefined threshold.
Service type: Proprietary laboratory diagnostic test (PLA) for blood/plasma biomarker analysis.
Typical site of service: Point-of-care or clinical laboratory setting, including emergency department and hospital-based point-of-care testing environments where the i–STAT platform is used.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient scenario involves an adult or adolescent presenting to the emergency department after a head trauma such as a fall, motor vehicle collision, sports injury, or assault. The patient has a mechanism concerning for traumatic brain injury (TBI) but has a noncontrast head CT that is normal or is being considered for CT decision support. The treating clinician orders the Abbott i-STAT TBI blood test to measure GFAP and UCH-L1 from a venous or plasma sample. Results report individual biomarker values and a combined interpretation of elevated or nonelevated based on the manufacturer's threshold. The workflow includes venipuncture or plasma draw, immediate point-of-care or central lab analysis using the proprietary i-STAT platform, documentation of the combined result in the chart, and integration of the result into clinical decision-making about CT imaging, observation, or discharge. Typical sites of service are the emergency department, urgent care centers, and hospital observation units. Service type: Proprietary Laboratory Analysis (PLA) — point-of-care or centralized lab proprietary assay.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Unspecified modifier (default) | Use when no other billing modifier applies; often the default submission for this PLA code. |
22 | Increased procedural services | Use when documentation supports substantially greater effort or resources to obtain or process the specimen beyond usual procedure. |
52 | Reduced services | Use when the procedure is partially reduced or not completed as expected, with documented reason. |
53 | Discontinued procedure | Use when the testing process was stopped due to patient condition or technical failure prior to completion. |
59 | Distinct procedural service | Use when a separate, distinct test or procedure is performed on the same date that is unrelated to the PLA test (apply cautiously with PLA code rules). |
76 | Repeat procedure by same physician | Use when the same provider repeats the GFAP/UCH-L1 assay during the same encounter for clinical reasons. |
77 | Repeat procedure by another physician | Use when a different provider repeats the test during the same encounter. |
90 | Reference (outside) laboratory | Use when the specimen is sent to a different CLIA-certified reference lab rather than performed locally on the i-STAT platform. |
91 | Repeat clinical diagnostic laboratory test | Use when a repeat quantitative test is performed and reporting is for the same analyte(s) on the same day. |
QW | CLIA-waived test | Use when the laboratory performing the point-of-care assay holds CLIA-waived status for the specific platform (if applicable). |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
2084P0800X | Emergency Medicine | ED physicians commonly order this test for acute head trauma triage. |
208D00000X | Clinical Laboratory Services | Laboratory directors and technicians responsible for performing and validating PLA tests. |
207RR0500X | Neurology | Neurologists may use results for inpatient TBI evaluation and triage. |
261QM0800X | Hospitalist | Hospital-based physicians caring for observation or admission decisions. |
2086S0123X | Sports Medicine | Team physicians and urgent care clinicians evaluating sports-related head injuries. |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
S06.0X0A | Concussion without loss of consciousness, initial encounter | Concussion is a primary indication for GFAP/UCH-L1 testing to assess for possible brain injury and guide imaging decisions. |
S06.5X0A | Traumatic subdural hemorrhage without loss of consciousness, initial encounter | Biomarkers may be used adjunctively when clinical exam and CT findings are considered for ongoing monitoring. |
S06.2X0A | Diffuse traumatic brain injury without loss of consciousness, initial encounter | Moderate to severe TBI contexts where biomarkers inform severity assessment and triage. |
S09.90XA | Unspecified injury of head, initial encounter | Used when head injury is documented but specifics are uncertain; biomarker testing assists in risk stratification. |
Z04.81 | Encounter for examination and observation following transport accident | Observation encounters after trauma commonly include biomarker testing as part of evaluation algorithms. |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
0570U | i-STAT TBI (Abbott) — GFAP and UCH-L1 assay, results reported individually and combined as elevated/nonelevated | Primary PLA code for the proprietary assay described; report when using Abbott i-STAT TBI platform. |
36415 | Collection of venous blood by venipuncture | Commonly performed immediately prior to sending blood for the GFAP/UCH-L1 assay; billed for specimen collection when reportable. |
85025 | Blood count; CBC with automated differential | Often ordered concurrently in head trauma workups to assess overall physiologic status, though not directly part of the PLA test. |
70450 | CT head/brain without contrast | Frequently performed before or after biomarker testing to evaluate for intracranial hemorrhage; biomarker results may influence decision to obtain CT. |
87086 | Culture, bacterial; quantitative colony count (example lab code) | Data not directly related to this PLA test but represents typical ancillary lab code types; include only when microbiology testing is performed concurrently. |
96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | Represents possible adjunctive interventions (eg, analgesia) during ED evaluation; may occur in same encounter but is not directly related to the PLA assay. |